Please login to the form below

Not currently logged in
Email:
Password:

Boehringer’s head of pharma heads for the exit

Comes amid restructuring and bolt-on deals to bolster business

BI

German drugmaker Boehringer Ingelheim is making changes at the top following the news that head of pharma Allan Hillgrove is retiring.

Hillgrove - a 37-year veteran at Boehringer - will step down by the end of the year and will be replaced by Carine Brouillon, who joined the company from Johnson & Johnson last year and is currently its head of prescription medicines.

Hillgrove

Allan Hillgrove

Company chairman Christian Boehringer said Hillgrove had made a significant contribution to the launch of new drugs like Ofev (nintedanib) for pulmonary fibrosis and diabetes therapy Jardiance (empagliflozin) and “thus the sustainable development of the company”.

Jardiance and Ofev are currently driving growth at the drugmaker, contributing almost €1.7bn to pharma revenues of €6.8bn in the first half of the year, and the company has also been particularly active of late in expanding it pipeline with bolt-on deals as it works through a business restructuring.

cb

Carine Bruillon

Recent deals have included a €325m acquisition of AMAL Therapeutics to gain access to its cancer vaccine technology, a $226m alliance with UK-listed biotech PureTech Health to develop a new approach to cancer immunotherapy, a €1.1bn licensing deal for an Ofev follow-up from Bridge Biotherapeutics, and an $870m tie-up with Yuhan for a non-alcoholic steatohepatitis (NASH) drug.

Brouillon will officially take over on 1 January 2020, taking over the responsibility of bedding in those new collaborations and spearheading new launches such as Ofev for systemic sclerosis.

The reshuffle is extending into other business units as well, with Joachim Hasenmaier - board member with responsibility for both animal and consumer health - stepping down after 18 years with the company.

Hasenmaier will also retire by the end of the year and will be succeeded as head of animal health by Jean Scheftsik de Szolnok, currently Boehringer’s animal health managing director in France.

28th August 2019

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...
Generation Z
The roaring ‘20s and Generation Z
How a new generation will shape pharma comms this decade...

Infographics